학술논문

Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate
Document Type
Journal Article
Source
Urology. Apr2003, Vol. 61 Issue 4, p730-735. 6p.
Subject
*PROSTATE-specific antigen
*RADIOTHERAPY
Language
ISSN
0090-4295
Abstract
: ObjectivesTo evaluate the significance of pretreatment prostate-specific antigen (pPSA) levels as a predictor of overall survival simultaneously with previously established prognostic factors. The pPSA level is a major predictor of treatment failure after radiotherapy and surgery, but to date has not been shown to predict survival.: MethodsThis analysis was based on data from 927 patients with clinically localized prostate cancer treated with radiotherapy alone between 1987 and 1998. These patients were stratified into four prognostic risk groups, and multivariate analysis was used to determine the independent impact of pPSA level on PSA failure, progression-free survival (death from any cause after PSA failure), and overall survival (death from any cause).: ResultsIn a multivariate analysis simultaneously considering the prognostic risk group, a pPSA level greater than or equal to 20 ng/mL was associated with a higher risk of PSA failure and worse progression-free and overall survival.: ConclusionsThe pPSA level is an independent predictor of survival in patients initially treated with radiotherapy alone. [Copyright &y& Elsevier]